Santhera

News

Wheelchair sign with trees in background

Santhera preps UK Duchenne drug launch after NICE says yes

Santhera will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks after getting the green light for NHS coverage.

News

Price deal opens door to NHS use of Santhera DMD drug

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement.

News

Santhera debuts DMD drug Agamree in Germany

Santhera’s new treatment for Duchenne muscular dystrophy Agamree has been launched in its first market, Germany, following its EU approval last month.

News

Santhera closes on first approval for DMD drug vamorolone

Swiss biotech Santhera is on the brink of its first regulatory approval for Duchenne muscular dystrophy treatment vamorolone, after getting a positive opinion on the drug

News

Catalyst throws lifeline to Santhera with $90m Duchenne deal

Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th Oc

News